天津医药

天津医药 ›› 2016, Vol. 44 ›› Issue (8): 967-969.doi: 10.11958/20160035

• 专题研究-心血管 • 上一篇    下一篇

超敏C 反应蛋白小于2 mg/L 的心绞痛患者抗血小板聚集治疗方案探讨

于伟， 周凤云， 刘青， 朱素娟， 靳晓华， 刘鹏   

  1. 济南， 山东省章丘市人民医院心内三科 （邮编250200）
  • 收稿日期:2016-01-25 修回日期:2016-05-05 出版日期:2016-08-15 发布日期:2016-08-22
  • 作者简介:于伟 （1975）， 男， 硕士， 主要从事冠心病及心律失常的介入诊治研究
  • 基金资助:
    章丘市人民医院面上课题 （201404）

Discussion on antiplatelet aggregation treatment options in high sensitive C-reactive protein less than 2 mg/L in patients with angina pectoris

YU Wei, ZHOU Fengyun, LIU Qing, ZHU Sujuan, JIN Xiaohua, LIU Peng   

  1. Department of Cardiology Three, the People’ s Hospital of Zhangqiu City, Shandong Province 250200, China
  • Received:2016-01-25 Revised:2016-05-05 Published:2016-08-15 Online:2016-08-22

PDF (PC)

3846

摘要： 摘要： 目的 比较双重抗血小板聚集和单用药物治疗超敏 C 反应蛋白 （hs-CRP） ＜2 mg/L 的心绞痛患者的效果差异。方法 选取因心绞痛 6～48 h 内就诊于我院且 hs-CRP＜2 mg/L 的患者 96 例， 采用随机数字表法分为阿司匹林组和联合治疗组， 每组 48 例。阿司匹林组患者口服拜阿司匹林 100 mg/d， 联合治疗组患者口服拜阿司匹林 10 mg/d 并加硫酸氢氯吡格雷片 75 mg/d， 治疗后 30 d 时对患者进行疗效评定， 并通过随访对患者 6 个月内出现复合终点事件的情况进行统计。结果 阿司匹林组总效率 ［81.25% （39/48）］ 与联合治疗组 ［85.42% （41/48）］ 差异无统计学意义 （χ2 =0.300， P＞0.05）。2 组患者治疗后的复合终点事件差异均无统计学意义 （P > 0.05）。结论 对于 hs-CRP＜ mg/L 的心绞痛患者， 即心血管事件风险相对较小的患者， 单一与双重抗血小板聚集治疗方案的效果无明显差异。

关键词: 超敏 C 反应蛋白, 心绞痛, 冠状动脉疾病, 抗血小板聚集治疗, 阿司匹林, 硫酸氢氯吡格雷雷

Abstract: Abstract: Objective To evaluate the feasibility of application of single and dual antiplatelet aggregation therapy in high sensitive C- reactive protein (hs- CRP) level in patients with angina pectoris. Methods Ninety- six hospitalized patients with angina 6~48 h (hs-CRP < 2 mg/L) were selected and randomly divided into single aspirin group (aspirin 100 mg/d, n=48) and aspirin plus clopidogrel combination therapy group (aspirin 100 mg/d and clopidogrel 75 mg/d, n=48). The efficacy was evaluated after 30-day treatment. Data of composite end points were analyzed by follow-up in patients within 6 months. Results The total effective rates were 85.42% for combination therapy group and 81.25% for single aspirin group. There was no significant difference in total effective rate between two groups (P > 0.05). There were no significant differences in events of composite end points in patients after treatment between two groups (P > 0.05). Conclusion For angina pectoris patients with hs-CRP < 2 mg/L, the risk of cardiovascular events is relatively little. There is no obvious difference in curative effect between single and dual antiplatelet aggreration therapies.

Key words:  hypersensitive C- reactive protein, angina pectoris, coronary artery disease, antiplatelet aggregation therapy, aspirin, clopidogrel hydrogen sulfate